Company: SXTPW
Filing Date: 2025-03-27
Form Type: S-1/A
Source: 0001013762-25-003353
Chunk: 188

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: S-1/A
Chunk 188
---
 exercise price of $6.85. 115 OUTSTANDING EQUITY AWARDS AT DECEMBER 31, 2024

| Name                                                        |     | Option                               
 Awards                               
 Number of securities underlying      
 unexercised options, exercisable (#) |       |     | Number of securities underlying       
 unexercised options unexercisable (#) |   |     | Equity                                                                              
 incentive plan awards: Number of securities underlying unexercised unearned options 
 (#)                                                                                 |       |     | Option         
 exercise price 
 ($)            |       |     | Option expiration  
 date               |     | Stock                                            
 Awards                                           
 Number                                           
 of shares or units of stock that have not vested 
 (#)                                              |   |     | Market                                                 
 value of shares or units of stock that have not vested 
 ($)                                                    |   |
|:------------------------------------------------------------|:----|:-------------------------------------|------:|:----|:--------------------------------------|:--|:----|:------------------------------------------------------------------------------------|------:|:----|:---------------|------:|:----|:-------------------|:----|:-------------------------------------------------|:--|:----|:-------------------------------------------------------|:--|
| Geoffrey Dow, President and Chief Executive                 
 Officer (Principal Executive Officer)(1)                    |     |                                      | 1,000 |     |                                       | - |     |                                                                                     | 4,000 |     | $              | 60.00 |     | July 16, 2034      |     |                                                  | - |     | $                                                      | - |
| Tyrone Miller, Chief Financial Officer (Principal Financial 
 and Accounting Officer)(2)                                  |     |                                      |   800 |     |                                       | - |     |                                                                                     | 3,200 |     | $              | 60.00 |     | July 16, 2034      |     |                                                  | - |     | $                                                      | - |
| Kristen Landon, Chief Commercial Officer(3)                 |     |                                      |   834 |     |                                       | - |     |                                                                                     | 3,333 |     | $              |  6.85 |     | September 26, 2034 |     |                                                  | - |     | $                                                      | - |

| (1) | Dr.                                                                                                                         
 Dow’s options to purchase a total of 5,000 shares of our common stock vest annually on the last date of each fiscal year in 
 five